Literature DB >> 12776950

Gene therapy for myocardial angiogenesis: with direct intramuscular gene transfer of naked deoxyribonucleic acid encoding vascular endothelial growth factor and cell transplantation of vascular endothelial growth factor transfected H9c2 myoblast.

Tsutomu Sugimoto1, Kiyoshige Inui, Yasuhisa Shimazaki.   

Abstract

OBJECTIVES: We studied the therapeutic potential of ex vivo vascular endothelial growth factor (VEGF) gene-transduced H9c2 cell transplantation for myocardial neovascularization.
METHODS: The left ventricular free wall of adult Sprague-Dawley rats was cryodamaged. Two weeks after, naked plasmid encoding VEGF (VEGF1: 1 1microg/100 microl, VEGF5: 5 microg/100 microl), or VEGF transfected H9c2 myoblasts (0.5 x 10(6) cells/200 microl) were injected into the center of scar tissue. Four weeks after cryoinjury, scar diameters in the each group were measured. Neovascularization in the scar tissue was then quantified histologically.
RESULTS: Average scar tissue diameter 4 weeks after cryoinjury was as follows: TE (controls): 6.77 +/- 0.31 mm, H9c2: 5.08 +/- 0.43 mm; VEGF1: 5.90 +/- 0.20 mm; VEGF5: 4.50 +/- 0.24 mm. Scar tissue diameter was smaller in the 3 groups than in the control group (p < 0.05). Capillary density by histological examination increased in naked plasmid injection groups (VEGF1: 1,209.9 +/- 305.3/mm2; VEGF5: 1,072.0 +/- 230.8/mm2) versus controls (708.2 +/- 144.9/mm2, p < 0.05, p < 0.05), and H9c2 cell transplantation group (1,379.4 +/- 391.6/mm2) versus controls (p < 0.05).
CONCLUSION: VEGF-transfected H9c2 myoblasts can be implanted and survive in infarcted myocardium. The ability to develop angiogenesis in the H9c2 cell transplantation group was markedly similar to direct myocardial injection in naked plasmid encoding VEGF groups.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776950     DOI: 10.1007/s11748-003-0030-7

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  21 in total

1.  Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.

Authors:  D W Losordo; P R Vale; J F Symes; C H Dunnington; D D Esakof; M Maysky; A B Ashare; K Lathi; J M Isner
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

Review 2.  Molecular analysis of blood vessel formation and disease.

Authors:  P Carmeliet; D Collen
Journal:  Am J Physiol       Date:  1997-11

3.  Cardiomyocyte transplantation improves heart function.

Authors:  R K Li; Z Q Jia; R D Weisel; D A Mickle; J Zhang; M K Mohabeer; V Rao; J Ivanov
Journal:  Ann Thorac Surg       Date:  1996-09       Impact factor: 4.330

Review 4.  A little VEGF goes a long way. Therapeutic angiogenesis by direct injection of vascular endothelial growth factor-encoding plasmid DNA.

Authors:  M W Majesky
Journal:  Circulation       Date:  1996-12-15       Impact factor: 29.690

5.  Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF.

Authors:  A Rivard; M Silver; D Chen; M Kearney; M Magner; B Annex; K Peters; J M Isner
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

6.  Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide.

Authors:  R M Tuder; B E Flook; N F Voelkel
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor.

Authors:  C Bauters; T Asahara; L P Zheng; S Takeshita; S Bunting; N Ferrara; J F Symes; J M Isner
Journal:  Circulation       Date:  1995-06-01       Impact factor: 29.690

8.  Regenerating functional myocardium: improved performance after skeletal myoblast transplantation.

Authors:  D A Taylor; B Z Atkins; P Hungspreugs; T R Jones; M C Reedy; K A Hutcheson; D D Glower; W E Kraus
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

9.  Morphological characterization of cardiomyocytes isolated from a transplantable cardiac tumor derived from transgenic mouse atria (AT-1 cells).

Authors:  J B Delcarpio; N A Lanson; L J Field; W C Claycomb
Journal:  Circ Res       Date:  1991-12       Impact factor: 17.367

10.  Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart.

Authors:  C A Mack; S R Patel; E A Schwarz; P Zanzonico; R T Hahn; A Ilercil; R B Devereux; S J Goldsmith; T F Christian; T A Sanborn; I Kovesdi; N Hackett; O W Isom; R G Crystal; T K Rosengart
Journal:  J Thorac Cardiovasc Surg       Date:  1998-01       Impact factor: 6.439

View more
  3 in total

1.  Potential treatment of hypoparathyroidism with recombinant plasmids encoding preproparathyroid hormone.

Authors:  D Liu; Y Zhu; C Yang; J Long; C Yao; J Li; S Wang
Journal:  J Endocrinol Invest       Date:  2011-09-27       Impact factor: 4.256

2.  MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases.

Authors:  Husnain Kh Haider; Ye Lei; Muhammad Ashraf
Journal:  Curr Opin Mol Ther       Date:  2008-12

3.  Novel Biomarker MicroRNAs for Subtyping of Acute Coronary Syndrome: A Bioinformatics Approach.

Authors:  Yujie Zhu; Yuxin Lin; Wenying Yan; Zhandong Sun; Zhi Jiang; Bairong Shen; Xiaoqian Jiang; Jingjing Shi
Journal:  Biomed Res Int       Date:  2016-12-01       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.